Dupixent approved in the EU as the first-ever targeted therapy for patients with COPD First-in-world approval of Dupixent for adults with uncontrolled COPD with raised blood eosinophils based on ...

Frexalimab new phase 2 data showed reduction of key biomarker of nerve cell damage in relapsing MS Frexalimab high-dose arm observed a 41% reduction in plasma neurofilament light chain ...

In her new role, Audrey will be responsible for Sanofi’s stakeholder engagement globally, and oversee the company’s corporate social responsibility strategy, not-for-profit Global Health Unit and ...

Sanofi and Biovac spearhead polio vaccine manufacturing capabilities in Africa Paris, June 20, 2024. Sanofi and Biovac, a Cape Town, South Africa-based biopharmaceutical company, announce today ...

Second quarter 2024 results will be reviewed by management during a live audio webcast with the financial community. The presentation will be followed by a Q&A session. We’re proud to be premium ...

Majority of patients in this age group with eosinophilic esophagitis receiving Dupixent achieved histologic remission, with improvements sustained up to one year Dupixent is the first-and-only ...

Seven oral presentations across the hemophilia portfolio reinforce Sanofi’s commitment to bring potential first- and best-in-class treatments to the rare blood disorders community Interim results from ...

Sanofi is working to address childhood cancer as a global health issue and to improve survival rates for children with cancer. The Sanofi Corporate Social Responsibility (CSR) Childhood Cancer R&D ...